CancerDrs

Leukemia clinical trials in Massachusetts

62 actively recruiting leukemia trials at 7 sites across Massachusetts.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • Tufts Medical Center Cancer Center Stoneham — Stoneham, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Massachusetts:
  • Tufts Children's Hospital — Boston, Massachusetts
  • Massachusetts General Hospital Cancer Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • Baystate Medical Center — Springfield, Massachusetts
  • UMass Memorial Medical Center - University Campus — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…

Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Massachusetts:
  • UMass Memorial Medical Center /ID# 270023 — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • UMass Memorial Medical Center - University Campus — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • Lahey Clinic — Burlington, Massachusetts
  • Lahey Clinic Peabody — Peabody, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Massachusetts:
  • Tufts Children's Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Massachusetts:
  • Tufts Medical Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • Lahey Clinic — Burlington, Massachusetts
  • Lahey Clinic Peabody — Peabody, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • UMass Memorial Medical Center - University Campus — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • UMass Memorial Medical Center - University Campus — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04811560
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…

Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Massachusetts:
  • Floating Hospital for Children at Tufts Medical Center — Boston, Massachusetts
  • Dana Faber Cancer Institute/ Boston Children's Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in Massachusetts:
  • Dana Farber Cancer Institute (DFCI) — Boston, Massachusetts
  • Massachusetts General Hospital — Boston, Massachusetts
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Massachusetts:
  • Boston Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Massachusetts:
  • Dana-Farber Cancer Institute ( Site 1013) — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blas…

Sponsor: Aptose Biosciences Inc.
NCT ID: NCT03850574
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer o…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06561360
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.

Sponsor: AstraZeneca
NCT ID: NCT06542250
Sites in Massachusetts:
  • Research Site — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a trea…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03824483
Sites in Massachusetts:
  • Massachusetts General Hospital (Data Collection and Specimen Analysis) — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be c…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04925479
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Lurbinectedin in FET-Fused Tumors

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05918640
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Ivosidenib as Post-HSCT Maintenance for AML

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

Sponsor: Massachusetts General Hospital
NCT ID: NCT06707493
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →

Showing 25 of 62 trials with sites in Massachusetts. See all leukemia trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27